Akebia Therapeutics and U.S. Renal Care announced that the interim analysis of the Vafseo Outcomes In Center Experience (VOICE) trial met predefined stopping criteria. Based on a June 1, 2026, data cutoff, the trial established non-inferiority and superiority of the primary composite endpoint of all-cause mortality and all-cause hospitalization. The analysis showed a win odds of 1.16 (95% CI 1.06, 1.28, p=0.0016) and a statistically significant decrease in hospitalizations for Vafseo versus standard-of-care erythropoiesis stimulating agents (1.11 versus 1.23 per patient year). Mortality rates showed no statistically significant difference between the two groups. Akebia Therapeutics is a biopharmaceutical company developing treatments for anemia due to chronic kidney disease.

At its 2026 Annual Meeting of Stockholders on June 17, 2026, Akebia Therapeutics approved an amendment to its Ninth Amended and Restated Certificate of Incorporation to increase authorized capital stock from 375 million to 525 million shares and authorized common stock from 350 million to 500 million shares. The company filed the Certificate of Amendment with the Delaware Secretary of State on June 18, 2026. Stockholders also elected Adrian Adams, Michael Rogers, and LeAnne M. Zumwalt as Class III directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved executive compensation and its annual voting frequency on an advisory basis. Akebia Therapeutics is a biopharmaceutical company that develops medicines to treat kidney disease.